IAM
PLRX icon

Innovis Asset Management’s Pliant Therapeutics PLRX Stock Holding History

Innovis Asset Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,762
Closed -$249K – 170
2023
Q2 		$249K Buy
+13,762
New +$326K 0.09% 137

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

Innovis Asset Management's PLRX Position: Q3 2023 in Review

Innovis Asset Management sold out of Pliant Therapeutics (PLRX) in Q3 2023, closing a stake of 13,762 shares — an estimated $249K sold.

Innovis Asset Management first reported a position in PLRX in Q2 2023 and held it in 1 quarter. The position peaked at $249K in Q2 2023. 136 funds tracked by Wall St. Rank hold PLRX as of Q3 2023.

  • Innovis Asset Management reported no remaining Pliant Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Innovis Asset Management sold 13,762 Pliant Therapeutics shares in Q3 2023, an estimated $249K.
  • Innovis Asset Management first reported a position in Pliant Therapeutics in Q2 2023 and held it in 1 quarter.
  • Innovis Asset Management's Pliant Therapeutics position peaked at $249K in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2023.

Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.